Latest Information Update: 28 Nov 2007
At a glance
- Originator OXiGENE
- Mechanism of Action Vascular disrupting agents
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 27 Nov 2006 No development reported - Preclinical for Solid tumours in USA (unspecified route)
- 25 Feb 2002 Preclinical trials in Solid tumours in USA